Recruiting
Phase 1

Cannabinoids

Sponsor:

Yale University

Code:

NCT04704271

Conditions

Cannabis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Inhaled THC

Placebo

Study Details

Brief summary:

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Conditions

Cannabis

Study ID

NCT04704271

Start date

Oct 9, 2019

Status verified date

Apr, 2026

Completion date

Dec 1, 2027

Anticipated

Primary completion date

Dec 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • At least one lifetime exposure to cannabis
  • Good physical and mental health

Exclusion Criteria:

  • Cannabis naïve individuals
  • Major current or recent stressors

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Delta-9-Tetrahydrocannabinol (THC)

4 mg vaporized THC will be administered.

placebo comparator: Placebo

Inhaled placebo (no active cannabinoids)

Interventions

Inhaled THC

4 mg inhaled THC

Placebo

Inhaled placebo (no active cannabinoids)

Primary outcome measure

  • Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS) [ Time Frame: Changes in "high" assessed over the following timepoints: baseline, +60, +80, +120, +180, +300 minutes after start of oral Dronabinol administration. ]
  • Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT) [ Time Frame: Baseline and +80 minutes after start of oral Dronabinol administration. ]

Central Contacts and Locations

Central contacts

Carly Hewes, BS

2039325711carly.hewes@yale.edu

Locations

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine

Recruiting

West Haven, Connecticut, United States, 06516

Contacts

Christina Luddy, BS

203-932-5711christina.luddy@yale.edu

Principal Investigator:

Mohini Ranganathan, MD

More Information

Sponsor

Yale University

Last update posted

Apr 29, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Yale University on 2026-04-29.